Abion and Janssen Research and Development, LLC, a Johnson & Johnson company have entered into a drug supply agreement to advance a combination clinical trial targeting EGFR-mutated non-small cell lung cancer (NSCLC).
The trial will investigate the efficacy of ABN401 (vabametkib), Abion’s c-MET inhibitor, in combination with Johnson & Johnson’s EGFR inhibitor, lazertinib. This collaboration aims to address resistance in patients with NSCLC that arises due to c-MET alterations.
Under this agreement, Abion will act as the sponsor of the clinical study, while Johnson & Johnson will provide lazertinib at no cost to support the trial.
